These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32297711)

  • 1. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
    Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
    Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.
    Lessire S; Douxfils J; Pochet L; Dincq AS; Larock AS; Gourdin M; Dogné JM; Chatelain B; Mullier F
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):129-138. PubMed ID: 27811211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
    Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
    Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
    Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
    Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
    Siriez R; Evrard J; Dogné JM; Pochet L; Bouvy C; Lessire S; Mullier F; Douxfils J
    Int J Lab Hematol; 2019 Apr; 41(2):250-261. PubMed ID: 30604921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
    Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
    J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.
    Ahn HS; Chae H; Kim Y; Lee HK; Kim H
    Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
    Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
    Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.